ID   KPCA_RAT                Reviewed;         672 AA.
AC   P05696;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   24-JUN-2015, entry version 165.
DE   RecName: Full=Protein kinase C alpha type;
DE            Short=PKC-A;
DE            Short=PKC-alpha;
DE            EC=2.7.11.13;
GN   Name=Prkca; Synonyms=Pkca;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=3387228; DOI=10.1093/nar/16.11.5199;
RA   Ono Y., Fujii T., Igarashi K., Kikkawa U., Ogita K., Nishizuka Y.;
RT   "Nucleotide sequences of cDNAs for alpha and gamma subspecies of rat
RT   brain protein kinase C.";
RL   Nucleic Acids Res. 16:5199-5200(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=3666147; DOI=10.1016/0014-5793(87)80291-0;
RA   Kikkawa U., Ogita K., Ono Y., Asaoka Y., Shearman M.S., Fujii T.,
RA   Ase K., Sekiguchi K., Igarashi K., Nishizuka Y.;
RT   "The common structure and activities of four subspecies of rat brain
RT   protein kinase C family.";
RL   FEBS Lett. 223:212-216(1987).
RN   [3]
RP   INTERACTION WITH SDPR.
RX   PubMed=9566962; DOI=10.1083/jcb.141.3.601;
RA   Mineo C., Ying Y.-S., Chapline C., Jaken S., Anderson R.G.W.;
RT   "Targeting of protein kinase Calpha to caveolae.";
RL   J. Cell Biol. 141:601-610(1998).
RN   [4]
RP   FUNCTION IN CELL CYCLE ARREST.
RX   PubMed=11076962; DOI=10.1083/jcb.151.4.763;
RA   Frey M.R., Clark J.A., Leontieva O., Uronis J.M., Black A.R.,
RA   Black J.D.;
RT   "Protein kinase C signaling mediates a program of cell cycle
RT   withdrawal in the intestinal epithelium.";
RL   J. Cell Biol. 151:763-778(2000).
RN   [5]
RP   FUNCTION IN CARDIAC HYPERTROPHY.
RX   PubMed=11864993; DOI=10.1083/jcb.200108062;
RA   Braz J.C., Bueno O.F., De Windt L.J., Molkentin J.D.;
RT   "PKC alpha regulates the hypertrophic growth of cardiomyocytes through
RT   extracellular signal-regulated kinase1/2 (ERK1/2).";
RL   J. Cell Biol. 156:905-919(2002).
RN   [6]
RP   FUNCTION IN HEART FAILURE, AND SUBCELLULAR LOCATION.
RX   PubMed=15271671; DOI=10.1152/ajpheart.00171.2004;
RA   Vijayan K., Szotek E.L., Martin J.L., Samarel A.M.;
RT   "Protein kinase C-alpha-induced hypertrophy of neonatal rat
RT   ventricular myocytes.";
RL   Am. J. Physiol. 287:H2777-H2789(2004).
RN   [7]
RP   REVIEW.
RX   PubMed=3045562; DOI=10.1038/334661a0;
RA   Nishizuka Y.;
RT   "The molecular heterogeneity of protein kinase C and its implications
RT   for cellular regulation.";
RL   Nature 334:661-665(1988).
RN   [8]
RP   FUNCTION.
RX   PubMed=19176525; DOI=10.1074/jbc.M808719200;
RA   Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.;
RT   "Phosphorylation of activation transcription factor-2 at serine 121 by
RT   protein kinase c controls c-Jun-mediated activation of
RT   transcription.";
RL   J. Biol. Chem. 284:8567-8581(2009).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 155-293 IN COMPLEX WITH
RP   PHOSPHATIDYLSERINE.
RX   PubMed=10562545; DOI=10.1093/emboj/18.22.6329;
RA   Verdaguer N., Corbalan-Garcia S., Ochoa W.F., Fita I.,
RA   Gomez-Fernandez J.C.;
RT   "Ca(2+) bridges the C2 membrane-binding domain of protein kinase
RT   Calpha directly to phosphatidylserine.";
RL   EMBO J. 18:6329-6338(1999).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 156-292 IN COMPLEX WITH
RP   PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE, MUTAGENESIS OF TYR-195;
RP   LYS-209; LYS-211 AND TRP-245, AND SUBCELLULAR LOCATION.
RX   PubMed=19346474; DOI=10.1073/pnas.0813099106;
RA   Guerrero-Valero M., Ferrer-Orta C., Querol-Audi J., Marin-Vicente C.,
RA   Fita I., Gomez-Fernandez J.C., Verdaguer N., Corbalan-Garcia S.;
RT   "Structural and mechanistic insights into the association of PKCalpha-
RT   C2 domain to PtdIns(4,5)P2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:6603-6607(2009).
CC   -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol
CC       (DAG)-dependent serine/threonine-protein kinase that is involved
CC       in positive and negative regulation of cell proliferation,
CC       apoptosis, differentiation, migration and adhesion, cardiac
CC       hypertrophy, angiogenesis, platelet function and inflammation, by
CC       directly phosphorylating targets such as RAF1, BCL2, CSPG4,
CC       TNNT2/CTNT, or activating signaling cascades involving MAPK1/3
CC       (ERK1/2) and RAP1GAP. Depending on the cell type, is involved in
CC       cell proliferation and cell growth arrest by positive and negative
CC       regulation of the cell cycle. Can promote cell growth by
CC       phosphorylating and activating RAF1, which mediates the activation
CC       of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A,
CC       which facilitates active cyclin-dependent kinase (CDK) complex
CC       formation. In cells stimulated by the phorbol ester PMA, can
CC       trigger a cell cycle arrest program which is associated with the
CC       accumulation of the hyper-phosphorylated growth-suppressive form
CC       of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B.
CC       Depending on the cell type, exhibits anti-apoptotic function and
CC       protects cells from apoptosis by suppressing the p53/TP53-mediated
CC       activation of IGFBP3, or mediates anti-apoptotic action by
CC       phosphorylating BCL2. During macrophage differentiation induced by
CC       macrophage colony-stimulating factor (CSF1), is translocated to
CC       the nucleus and is associated with macrophage development. After
CC       wounding, translocates from focal contacts to lamellipodia and
CC       participates in the modulation of desmosomal adhesion. Plays a
CC       role in cell motility by phosphorylating CSPG4, which induces
CC       association of CSPG4 with extensive lamellipodia at the cell
CC       periphery and polarization of the cell accompanied by increases in
CC       cell motility. Negatively regulates myocardial contractility and
CC       positively regulates angiogenesis, platelet aggregation and
CC       thrombus formation in arteries. Mediates hypertrophic growth of
CC       neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-
CC       dependent signaling pathway, and upon PMA treatment, is required
CC       to induce cardiomyocyte hypertrophy up to heart failure and death,
CC       by increasing protein synthesis, protein-DNA ratio and cell
CC       surface area. Regulates cardiomyocyte function by phosphorylating
CC       cardiac troponin T (TNNT2/CTNT), which induces significant
CC       reduction in actomyosin ATPase activity, myofilament calcium
CC       sensitivity and myocardial contractility. In angiogenesis, is
CC       required for full endothelial cell migration, adhesion to
CC       vitronectin (VTN), and vascular endothelial growth factor A
CC       (VEGFA)-dependent regulation of kinase activation and vascular
CC       tube formation. Involved in the stabilization of VEGFA mRNA at
CC       post-transcriptional level and mediates VEGFA-induced cell
CC       proliferation. In the regulation of calcium-induced platelet
CC       aggregation, mediates signals from the CD36/GP4 receptor for
CC       granule release, and activates the integrin heterodimer ITGA2B-
CC       ITGB3 through the RAP1GAP pathway for adhesion. During response to
CC       lipopolysaccharides (LPS), may regulate selective LPS-induced
CC       macrophage functions involved in host defense and inflammation.
CC       But in some inflammatory responses, may negatively regulate NF-
CC       kappa-B-induced genes, through IL1A-dependent induction of NF-
CC       kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-
CC       tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1,
CC       which modulates EIF4G1 binding to MKNK1 and may be involved in the
CC       regulation of EIF4E phosphorylation. Phosphorylates KIT, leading
CC       to inhibition of KIT activity. Phosphorylates ATF2 which promotes
CC       cooperation between ATF2 and JUN, activating transcription.
CC       {ECO:0000269|PubMed:11076962, ECO:0000269|PubMed:11864993,
CC       ECO:0000269|PubMed:15271671, ECO:0000269|PubMed:19176525}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000250};
CC       Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2
CC       domain. {ECO:0000250};
CC   -!- ENZYME REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB
CC       and PRKCG) are activated by calcium and diacylglycerol (DAG) in
CC       the presence of phosphatidylserine. Three specific sites; Thr-497
CC       (activation loop of the kinase domain), Thr-638 (turn motif) and
CC       Ser-657 (hydrophobic region), need to be phosphorylated for its
CC       full activation.
CC   -!- SUBUNIT: Interacts with ADAP1/CENTA1, CSPG4 and PRKCABP. Binds to
CC       SDPR in the presence of phosphatidylserine (By similarity).
CC       Interacts with PICK1 (via PDZ domain) (By similarity). Interacts
CC       with TRIM41 (By similarity). Recruited in a circadian manner into
CC       a nuclear complex which also includes BMAL1 and GNB2L1/RACK1 (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P34901:Sdc4; NbExp=3; IntAct=EBI-935801, EBI-1173182;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral
CC       membrane protein. Mitochondrion membrane {ECO:0000250}; Peripheral
CC       membrane protein {ECO:0000250}. Nucleus. Note=Translocated to the
CC       nucleus upon treatment with PMA or IGF1.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 AGC-kinase C-terminal domain.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 C2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00041}.
CC   -!- SIMILARITY: Contains 2 phorbol-ester/DAG-type zinc fingers.
CC       {ECO:0000255|PROSITE-ProRule:PRU00226}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X07286; CAA30266.1; -; mRNA.
DR   PIR; S02248; KIRTC.
DR   UniGene; Rn.86669; -.
DR   PDB; 1DSY; X-ray; 2.60 A; A=155-293.
DR   PDB; 3GPE; X-ray; 2.00 A; A=156-292.
DR   PDB; 3RDJ; X-ray; 1.90 A; A=156-292.
DR   PDB; 3TWY; X-ray; 1.50 A; A=156-292.
DR   PDB; 4L1L; X-ray; 1.60 A; A=155-293.
DR   PDBsum; 1DSY; -.
DR   PDBsum; 3GPE; -.
DR   PDBsum; 3RDJ; -.
DR   PDBsum; 3TWY; -.
DR   PDBsum; 4L1L; -.
DR   ProteinModelPortal; P05696; -.
DR   SMR; P05696; 37-292, 336-666.
DR   IntAct; P05696; 6.
DR   MINT; MINT-86103; -.
DR   STRING; 10116.ENSRNOP00000004699; -.
DR   BindingDB; P05696; -.
DR   ChEMBL; CHEMBL2855; -.
DR   PhosphoSite; P05696; -.
DR   PaxDb; P05696; -.
DR   PRIDE; P05696; -.
DR   RGD; 3395; Prkca.
DR   eggNOG; COG0515; -.
DR   HOGENOM; HOG000233022; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P05696; -.
DR   PhylomeDB; P05696; -.
DR   BRENDA; 2.7.11.13; 5301.
DR   EvolutionaryTrace; P05696; -.
DR   PRO; PR:P05696; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:RGD.
DR   GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:RGD.
DR   GO; GO:0043005; C:neuron projection; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0043234; C:protein complex; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; IDA:RGD.
DR   GO; GO:0004697; F:protein kinase C activity; IDA:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007568; P:aging; IEP:RGD.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0021955; P:central nervous system neuron axonogenesis; IMP:RGD.
DR   GO; GO:0045184; P:establishment of protein localization; TAS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:RGD.
DR   GO; GO:0007611; P:learning or memory; IMP:RGD.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0045822; P:negative regulation of heart contraction; IMP:RGD.
DR   GO; GO:0017148; P:negative regulation of translation; IMP:RGD.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:RGD.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:RGD.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IDA:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:2000707; P:positive regulation of dense core granule biogenesis; ISS:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IMP:RGD.
DR   GO; GO:0031666; P:positive regulation of lipopolysaccharide-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045651; P:positive regulation of macrophage differentiation; ISS:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IMP:RGD.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:RGD.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:RGD.
DR   GO; GO:0090330; P:regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0048259; P:regulation of receptor-mediated endocytosis; IMP:RGD.
DR   GO; GO:0046677; P:response to antibiotic; IEP:RGD.
DR   GO; GO:0051412; P:response to corticosterone; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IMP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IMP:RGD.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0043434; P:response to peptide hormone; IEP:RGD.
DR   GO; GO:0000302; P:response to reactive oxygen species; IMP:RGD.
DR   GO; GO:0009636; P:response to toxic substance; IEP:RGD.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014375; Protein_kinase_C_a/b/g.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000550; PKC_alpha; 1.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Angiogenesis; Apoptosis; ATP-binding;
KW   Calcium; Cell adhesion; Cell membrane; Complete proteome; Cytoplasm;
KW   Kinase; Membrane; Metal-binding; Mitochondrion; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P17252}.
FT   CHAIN         2    672       Protein kinase C alpha type.
FT                                /FTId=PRO_0000055682.
FT   DOMAIN      172    260       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      339    597       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      598    668       AGC-kinase C-terminal.
FT   ZN_FING      36     86       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     101    151       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     345    353       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    463    463       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   METAL       186    186       Calcium 1; via carbonyl oxygen.
FT   METAL       187    187       Calcium 1.
FT   METAL       187    187       Calcium 2.
FT   METAL       193    193       Calcium 2.
FT   METAL       246    246       Calcium 1.
FT   METAL       246    246       Calcium 2.
FT   METAL       247    247       Calcium 2; via carbonyl oxygen.
FT   METAL       248    248       Calcium 1.
FT   METAL       248    248       Calcium 2.
FT   METAL       248    248       Calcium 3.
FT   METAL       252    252       Calcium 3; via carbonyl oxygen.
FT   METAL       254    254       Calcium 1.
FT   METAL       254    254       Calcium 3.
FT   BINDING     195    195       Inositol phosphate group.
FT   BINDING     245    245       Inositol phosphate group.
FT   BINDING     368    368       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P17252}.
FT   MOD_RES     226    226       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P17252}.
FT   MOD_RES     497    497       Phosphothreonine; by PDPK1.
FT                                {ECO:0000250}.
FT   MOD_RES     628    628       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P17252}.
FT   MOD_RES     631    631       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000255}.
FT   MOD_RES     638    638       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     651    651       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P17252}.
FT   MOD_RES     657    657       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04409}.
FT   MOD_RES     658    658       Phosphotyrosine; by SYK. {ECO:0000250}.
FT   MUTAGEN     195    195       Y->S: Reduced phosphatidylinositol 4,5-
FT                                bisphosphate recognition and impaired
FT                                membrane docking. Loss of
FT                                phosphatidylinositol 4,5-bisphosphate-
FT                                binding and strong decrease of membrane
FT                                docking; when associated with A-209; A-
FT                                211 and A-245.
FT                                {ECO:0000269|PubMed:19346474}.
FT   MUTAGEN     209    209       K->A: Loss of phosphatidylinositol 4,5-
FT                                bisphosphate-binding and strong decrease
FT                                of membrane docking; when associated with
FT                                S-195; A-211 and A-245.
FT                                {ECO:0000269|PubMed:19346474}.
FT   MUTAGEN     211    211       K->A: Loss of phosphatidylinositol 4,5-
FT                                bisphosphate-binding and strong decrease
FT                                of membrane docking; when associated with
FT                                S-195; A-209 and A-245.
FT                                {ECO:0000269|PubMed:19346474}.
FT   MUTAGEN     245    245       W->A: Reduced phosphatidylinositol 4,5-
FT                                bisphosphate recognition and impaired
FT                                membrane docking. Loss of
FT                                phosphatidylinositol 4,5-bisphosphate-
FT                                binding and strong decrease of membrane
FT                                docking; when associated with S-195; A-
FT                                209 and A-211.
FT                                {ECO:0000269|PubMed:19346474}.
FT   STRAND      161    169       {ECO:0000244|PDB:3TWY}.
FT   STRAND      172    182       {ECO:0000244|PDB:3TWY}.
FT   STRAND      194    201       {ECO:0000244|PDB:3TWY}.
FT   STRAND      222    230       {ECO:0000244|PDB:3TWY}.
FT   HELIX       233    237       {ECO:0000244|PDB:3TWY}.
FT   STRAND      239    246       {ECO:0000244|PDB:3TWY}.
FT   STRAND      249    251       {ECO:0000244|PDB:3TWY}.
FT   STRAND      254    262       {ECO:0000244|PDB:3TWY}.
FT   HELIX       263    268       {ECO:0000244|PDB:3TWY}.
FT   STRAND      271    276       {ECO:0000244|PDB:3TWY}.
FT   HELIX       280    283       {ECO:0000244|PDB:3TWY}.
FT   STRAND      288    290       {ECO:0000244|PDB:1DSY}.
SQ   SEQUENCE   672 AA;  76792 MW;  94889E7339C17719 CRC64;
     MADVYPANDS TASQDVANRF ARKGALRQKN VHEVKDHKFI ARFFKQPTFC SHCTDFIWGF
     GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPDTDDPRS KHKFKIHTYG SPTFCDHCGS
     LLYGLIHQGM KCDTCDMNVH KQCVINVPSL CGMDHTEKRG RIYLKAEVTD EKLHVTVRDA
     KNLIPMDPNG LSDPYVKLKL IPDPKNESKQ KTKTIRSTLN PQWNESFTFK LKPSDKDRRL
     SVEIWDWDRT TRNDFMGSLS FGVSELMKMP ASGWYKLLNQ EEGEYYNVPI PEGDEEGNVE
     LRQKFEKAKL GPAGNKVISP SEDRKQPSNN LDRVKLTDFN FLMVLGKGSF GKVMLADRKG
     TEELYAIKIL KKDVVIQDDD VECTMVEKRV LALLDKPPFL TQLHSCFQTV DRLYFVMEYV
     NGGDLMYHIQ QVGKFKEPQA VFYAAEISIG LFFLHKRGII YRDLKLDNVM LDSEGHIKIA
     DFGMCKEHMM DGVTTRTFCG TPDYIAPEII AYQPYGKSVD WWAYGVLLYE MLAGQPPFDG
     EDEDELFQSI MEHNVSYPKS LSKEAVSICK GLMTKHPAKR LGCGPEGERD VREHAFFRRI
     DWEKLENREI QPPFKPKVCG KGAENFDKFF TRGQPVLTPP DQLVIANIDQ SDFEGFSYVN
     PQFVHPILQS AV
//
